Clarity Pharmaceuticals

Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company that aims to address the growing need for the use of radiopharmaceuticals in oncology. The company is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT is a next-generation disruptive platform in radiopharmaceuticals that employs the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. Clarity's TCT products offer a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. The company has a diverse range of products in clinical trials addressing both large indications such as prostate cancer and breast cancer, as well as small and orphan indications like neuroendocrine tumors (NETs) and neuroblastoma. Clarity's ultimate goal is to improve treatment outcomes for children and adults with cancer. Founded in 2010 and headquartered in Australia, Clarity Pharmaceuticals recently secured a $4.00M Venture Round investment on 29 June 2017. With its innovative approach to radiopharmaceuticals and a strong focus on addressing critical unmet needs in oncology, Clarity Pharmaceuticals presents an intriguing opportunity for potential investors looking to support advancements in cancer treatment.